Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

  
 
  
Reply to this topic

IQ3, IQ3CORP LIMITED
nipper
post Posted: Nov 20 2020, 02:04 PM
  Quote Post


Posts: 7,737
Thanks: 2598


This old chestnut has reappeared.
QUOTE
Clocking almost 300km/h at times, race cars zoomed around the Bathurst 12 hour endurance race. One car, a blue yellow Porsche, stood out among the hurtling metal because its bonnet sponsor was a money-losing biotechnology outfit.At first glance, a sharemarket listed biotechnology organisation's race car sponsorship between 2015 and 2018 seems puzzling.

But the sponsor, iQ Group Global, argued "innovation" and "endurance" were common features between it and the Porsche. It even hashtagged the terms on social media.

Two years later, Sydney based iQ is behind a new marketing ploy ... an aggressive one raising the eyebrows of market overseers.

Using advertisements of an ageing white couple strolling along a beach with their golden retriever, iQ is promoting Ethical Bioscience Investments and its spectacular fixed returns, such as 9 per cent on money to be repaid after 12 months, or 11 per cent over 24 months.

It is more than an offer on a swanky looking website. Ethical Bioscience is appearing in new age Instagram feeds and Facebook pages, in online advertisements including in The Australian Financial Review, and in promotions for investment newsletters for subscribers to the Switzer Financial Group of Peter Switzer.

But Ethical Bioscience's actual investments are unclear.

Glossy advertising only refers to selecting late discovery or preclinical stage life science companies, with assets that have potential for significant value appreciation. This advertising offers reassurance about risk, saying investments are carefully vetted and validated by our scientific and investment committees.

But biotechnology is traditionally a highly speculative sector where products can take more than a decade to reach markets. Multiple industry sources also say such debt notes, and this investment offers quarterly returns, are almost unheard of.....
https://www.afr.com/companies/financial-ser...20201120-p56gd5



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Apr 8 2016, 10:11 AM
  Quote Post


Posts: 7,737
Thanks: 2598


QUOTE
iQ3 is pleased to announce that it has syndicated an investor consortium which include iQ Group Global entities, to enter into a joint venture to develop and commercialise a first in class oncology, novel biologic compound and biomarker. The intellectual property was originally developed at McGill University in Montreal Canada.

In addition, iQ3 has has also been appointed to act as a lead advisor to the consortium and will prepare the joint venture for its next growth phase.

CEO Dr George Syrmalis stated “this is an incredible opportunity which gives Australian Life Science investors access to World Class Biotech assets and creates the opportunity to commercialize a significant novel compound which in this case also involves an accompanying biomarker. This is a strategically significant deal that iQ3 has advised on and signifies the important role we act in Australia’s drive for innovation.

It is expected that iQ3 will be realising further revenue, both in fees and equity, whilst contributing to Australia’s protagonistic role in the global life science arena”

first signs of life, since IPO



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: May 19 2015, 05:36 PM
  Quote Post


Posts: 7,737
Thanks: 2598


In Reply To: ShareScene.com's post @ May 19 2015, 05:24 PM

from their website
QUOTE
IQ3 Corp is working with companies developing life changing technologies (eg Alzheimer's, Cancer, Osteoporosis, Cardiovascular) and have the ability to enter these investments at a much earlier stage than most. They .... combine scientific background with funding capabilities to enter at the discovery stage of a compound, as opposed to investing at Phase 2 or 3 where a lot of the value created is already behind.

Biotech investors in Australia often think by investing at a later stage they are "de-risking" but that is not the case, as you are actually moving closer to a no outcome from the regulatory bodies, exhaustion of capital, and no guarantees that the product will sell even if it makes it to market. We take biotech compounds from discovery to preclinical, provide capital, provide scientific expertise (through our subsidiary iQNovate (a Listed R&D company) by creating the clinical plan to take compound to Phase 1 trials.

During this time we position the company for a public listing both in Australia and internationally. The US and European markets have much higher valuations for biotech. At this stage we have the ability to exit the investment or continue on with a reduced stake.

listed at 30c on Monday, hit 60c on Tuesday = nice stag for some





--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
ShareScene.com
post Posted: May 19 2015, 05:24 PM
  Quote Post



Posts: 4,290
Thanks: 206


Added by request:

iQ3Corp Limited (IQ3)

Regards,

ShareScene Admin

 
 



Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING